Please upgrade your browser.
The pivotal Phase 3 KEYNOTE-426 clinical trial investigating Keytruda (pembrolizumab) anti-PD-1 therapy in combination with Inlyta (axitinib), a tyrosine kinase inhibitor (TKI) improved both overall survival (OS) and delayed the time to cancer progression compared to Sutent (sunitinib) when used in the first-line treatment of advanced or metastatic renal cell carcinoma (RCC).
Overall cancer death rates continue to decline in both men and women and across major ethnic and racial groups, according to the annual Status of Cancer report published in the Journal of the National Cancer Institute.
Treatment for renal cell cancer is tailored to each individual and may include surgery, precision cancer medicines, immunotherapy and chemotherapy. Radiation therapy is not typically used for the treatment of renal cell cancer. The specific treatment depends on the stage and genomic profile of the cancer.
Patients with Stage I renal cell cancer have a primary cancer that is less than 7 centimeters in size (about 3 inches). The cancer is limited to the kidney, and has not spread to lymph nodes or distant sites.
Patients with Stage IV renal cell cancer have cancer that has spread to distant sites in the body, invaded directly into local structures, or has spread to more than one lymph node. Stage IV disease is also known as metastatic cancer.
This article explains the importance of checking your medical records for mistakes.
French music producer donates all proceeds of his song, "I Want A Miracle" to the Kidney Cancer Association
Dr. Brian Rini and Dr. David F. McDermott discuss two different clinical trials for #KidneyCancer patients.
Insights From: Brian Rini,MD, Cleveland Clinic Main Campus; David F. McDermott, MD, Harvard Cancer Center
RCC is the seventh leading cause of cancer deaths in the U.S. Check out this article for an overview of the condition.
|Powered by NeonCRM|